Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.505
-0.004 (-0.84%)
Nov 21, 2024, 12:01 PM EST - Market open
Unicycive Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | 0.68 | 0.95 | - | - | - | |
| Revenue Growth (YoY) | - | -29.02% | - | - | - | - | |
| Gross Profit | - | 0.68 | 0.95 | - | - | - | |
| Selling, General & Admin | 10.21 | 8.55 | 6.57 | 2.9 | 1.01 | 1.17 | |
| Research & Development | 18.96 | 12.9 | 12.44 | 6.08 | 1.02 | 0.8 | |
| Operating Expenses | 29.17 | 21.45 | 19 | 8.98 | 2.02 | 1.96 | |
| Operating Income | -29.17 | -20.77 | -18.05 | -8.98 | -2.02 | -1.96 | |
| Interest Expense | -0.07 | -0.08 | -0.01 | -0.63 | -0.24 | -0.14 | |
| Interest & Investment Income | 1.09 | 0.62 | - | - | - | - | |
| Other Non Operating Income (Expenses) | 5.15 | -10.3 | - | - | - | - | |
| EBT Excluding Unusual Items | -23 | -30.54 | -18.06 | -9.61 | -2.26 | -2.1 | |
| Other Unusual Items | - | - | - | -0.41 | - | -0.06 | |
| Pretax Income | -23 | -30.54 | -18.06 | -10.02 | -2.26 | -2.17 | |
| Net Income | -23 | -30.54 | -18.06 | -10.02 | -2.26 | -2.17 | |
| Preferred Dividends & Other Adjustments | 1.1 | 0.87 | - | - | - | - | |
| Net Income to Common | -24.1 | -31.41 | -18.06 | -10.02 | -2.26 | -2.17 | |
| Shares Outstanding (Basic) | 49 | 25 | 15 | 12 | 8 | 8 | |
| Shares Outstanding (Diluted) | 49 | 25 | 15 | 12 | 8 | 8 | |
| Shares Change (YoY) | 151.45% | 62.98% | 28.96% | 37.37% | 4.68% | 20.35% | |
| EPS (Basic) | -0.49 | -1.28 | -1.20 | -0.86 | -0.27 | -0.27 | |
| EPS (Diluted) | -0.49 | -1.28 | -1.20 | -0.86 | -0.27 | -0.27 | |
| Free Cash Flow | -26.52 | -18.3 | -15.65 | -5.8 | -1.46 | -1.18 | |
| Free Cash Flow Per Share | -0.54 | -0.75 | -1.04 | -0.50 | -0.17 | -0.14 | |
| Gross Margin | - | 100.00% | 100.00% | - | - | - | |
| Operating Margin | - | -3077.63% | -1898.21% | - | - | - | |
| Profit Margin | - | -4653.48% | -1898.84% | - | - | - | |
| Free Cash Flow Margin | - | -2710.37% | -1645.95% | - | - | - | |
| EBITDA | -29.15 | -20.77 | -18.05 | -8.98 | - | - | |
| D&A For EBITDA | 0.02 | 0.01 | 0.01 | 0 | - | - | |
| EBIT | -29.17 | -20.77 | -18.05 | -8.98 | -2.02 | -1.96 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.